Serum neurofilament light chain: a novel biomarker for cardiovascular diseases in individuals without hypertension.
Cardiovascular disease
Cardiovascular risk
NHANES
Risk prediction
Serum neurofilament light chain
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 10 2024
30 10 2024
Historique:
received:
25
09
2024
accepted:
22
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Serum neurofilament light chain (sNFL) is a biomarker for axonal injury. Previous studies have linked sNFL levels to cardiovascular risk factors such as diabetes and hypertension, but its association with cardiovascular diseases (CVD) remains unclear. This study aims to explore the association between sNFL and CVD and evaluates its predictive value. Utilizing NHANES 2013-2014 data, this study included 2,035 participants aged ≥ 20 years with measured sNFL quantified using a Siemens immunoassay. CVD was self-reported and included myocardial infarction, stroke, heart failure, coronary heart disease, or angina. Logistic regression models assessed the association between sNFL levels and CVD. The predictive value of sNFL for CVD was evaluated using area under the curve (AUC) and DeLong test. Participants with higher sNFL levels were typically older, male, non-Hispanic white, smokers, and had lower socioeconomic status, higher CVD, hypertension, and diabetes prevalence. Higher sNFL levels were significantly associated with increased odds of CVD (adjusted OR = 1.41, 95% CI: 1.05-1.88). The association was significant in non-hypertensive individuals (OR = 2.72, 95% CI: 1.61-4.62) but not in hypertensive individuals (OR = 1.13, 95% CI: 0.81-1.56). sNFL addition to traditional risk models improved predictive accuracy, especially in non-hypertensive individuals (AUC from 0.827 to 0.856). sNFL levels are significantly associated with CVD in the general population, with a strong predictive value in non-hypertensive individuals. Future longitudinal studies should validate sNFL's efficacy in various populations and explore the underlying mechanisms of its relationship with hypertension and CVD.
Identifiants
pubmed: 39478121
doi: 10.1038/s41598-024-77446-y
pii: 10.1038/s41598-024-77446-y
doi:
Substances chimiques
Biomarkers
0
Neurofilament Proteins
0
neurofilament protein L
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26117Informations de copyright
© 2024. The Author(s).
Références
Bjornevik, K. et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol. 77(1), 58–64 (2020).
doi: 10.1001/jamaneurol.2019.3238
pubmed: 31515562
Moseby-Knappe, M. et al. Serum neurofilament light chain for prognosis of outcome after cardiac arrest. JAMA Neurol. 76(1), 64–71 (2019).
doi: 10.1001/jamaneurol.2018.3223
pubmed: 30383090
Siller, N. et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Multiple Scler. J. 25(5), 678–686 (2019).
doi: 10.1177/1352458518765666
Mollenhauer, B. et al. Validation of serum neurofilament light chain as a biomarker of Parkinson’s disease progression. Mov. Disord. 35(11), 1999–2008 (2020).
doi: 10.1002/mds.28206
pubmed: 32798333
Rohrer, J. D. et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology. 87(13), 1329–1336 (2016).
doi: 10.1212/WNL.0000000000003154
pubmed: 27581216
Abu-Rumeileh, S. et al. The multifaceted role of neurofilament light chain protein in non-primary neurological diseases. Brain. 146(2), 421–437 (2023).
doi: 10.1093/brain/awac328
pubmed: 36083979
Barro, C., Chitnis, T. & Weiner, H. L. Blood neurofilament light: a critical review of its application to neurologic disease. Ann. Clin. Transl. Neurol. 7(12), 2508–2523 (2020).
doi: 10.1002/acn3.51234
pubmed: 33146954
Polymeris, A. A. et al. Serum neurofilament light in atrial fibrillation: clinical, neuroimaging and cognitive correlates. Brain Commun. 2(2), fcaa166 (2020).
doi: 10.1093/braincomms/fcaa166
pubmed: 33381755
Korley, F. K. et al. Serum NfL (neurofilament light chain) levels and incident stroke in adults with diabetes mellitus. Stroke. 50(7), 1669–1675 (2019).
doi: 10.1161/STROKEAHA.119.024941
pubmed: 31138085
Mielke, M. M. et al. Plasma and CSF neurofilament light: relation to longitudinal neuroimaging and cognitive measures. Neurology. 93(3), e252–e260 (2019).
doi: 10.1212/WNL.0000000000007767
pubmed: 31182505
Freedman, M. S. et al. Guidance for use of neurofilament light chain as a cerebrospinal fluid and blood biomarker in multiple sclerosis management. EBioMedicine. 101, 104970 (2024).
doi: 10.1016/j.ebiom.2024.104970
pubmed: 38354532
Xie, R., Liu, X., Wu, H., Liu, M. & Zhang, Y. Associations between systemic immune-inflammation index and abdominal aortic calcification: results of a nationwide survey. Nutr. Metab. Cardiovasc. Dis. 33(7), 1437–1443 (2023).
doi: 10.1016/j.numecd.2023.04.015
pubmed: 37156667
Xie, R. & Zhang, Y. Associations between dietary flavonoid intake with hepatic steatosis and fibrosis quantified by VCTE: evidence from NHANES and FNDDS. Nutr. Metab. Cardiovasc. Dis. 33(6), 1179–1189 (2023).
doi: 10.1016/j.numecd.2023.03.005
pubmed: 36964061
Liang, N. et al. Association of Dietary Retinol Intake and serum neurofilament light chain levels: results from NHANES 2013–2014. Nutrients 16(11). (2024).
Yang, A. M., Chu, P. L., Wang, C. & Lin, C. Y. Association between urinary glyphosate levels and serum neurofilament light chain in a representative sample of US adults: NHANES 2013–2014. J. Expo Sci. Environ. Epidemiol. 34(2), 287–293 (2024).
doi: 10.1038/s41370-023-00594-2
pubmed: 37674008
Zhang, Q., Xiao, S., Jiao, X. & Shen, Y. The triglyceride-glucose index is a predictor for cardiovascular and all-cause mortality in CVD patients with diabetes or pre-diabetes: evidence from NHANES 2001–2018. Cardiovasc. Diabetol. 22(1), 279 (2023).
doi: 10.1186/s12933-023-02030-z
pubmed: 37848879
pmcid: 10583314
Hviid, C. V. B., Madsen, A. T. & Winther-Larsen, A. Biological variation of serum neurofilament light chain. Clin. Chem. Lab. Med. (CCLM). 60(4), 569–575 (2022).
doi: 10.1515/cclm-2020-1276
pubmed: 33759425
Manouchehrinia, A. et al. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann. Clin. Transl. Neurol. 7(1), 139–143 (2020).
doi: 10.1002/acn3.50972
pubmed: 31893563
Ciardullo, S. et al. Diabetes Mellitus is Associated with higher serum neurofilament light chain levels in the General US Population. J. Clin. Endocrinol. Metab. 108(2), 361–367 (2023).
doi: 10.1210/clinem/dgac580
pubmed: 36196647
Stekhoven, D. J. & Bühlmann, P. MissForest–non-parametric missing value imputation for mixed-type data. Bioinformatics. 28(1), 112–118 (2012).
doi: 10.1093/bioinformatics/btr597
pubmed: 22039212
Zhang, Y. et al. Associations between weight-adjusted waist index and bone mineral density: results of a nationwide survey. BMC Endocr. Disord. 23(1), 162 (2023).
doi: 10.1186/s12902-023-01418-y
pubmed: 37537589
DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 837–845 (1988).
Cortese, M. et al. Vitamin D, smoking, EBV, and long-term cognitive performance in MS: 11-year follow-up of BENEFIT. Neurology. 94(18), e1950–e1960 (2020).
doi: 10.1212/WNL.0000000000009371
pubmed: 32300060
Arnold, S. V. et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 141(19), e779–e806 (2020).
doi: 10.1161/CIR.0000000000000766
pubmed: 32279539
Kjeldsen, S. E. Hypertension and cardiovascular risk: General aspects. Pharmacol. Res. 129, 95–99 (2018).
doi: 10.1016/j.phrs.2017.11.003
pubmed: 29127059
Guzik, T. J. & Touyz, R. M. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension. 70(4), 660–667 (2017).
doi: 10.1161/HYPERTENSIONAHA.117.07802
pubmed: 28784646
Ruan, C-C. & Gao, P-J. Role of complement-related inflammation and vascular dysfunction in hypertension. Hypertension. 73(5), 965–971 (2019).
doi: 10.1161/HYPERTENSIONAHA.118.11210
pubmed: 30929519
Fisher, J. & Paton, J. The sympathetic nervous system and blood pressure in humans: implications for hypertension. J. Hum. Hypertens. 26(8), 463–475 (2012).
doi: 10.1038/jhh.2011.66
pubmed: 21734720
Soleimani, M., Barone, S., Luo, H. & Zahedi, K. Pathogenesis of hypertension in metabolic syndrome: the role of fructose and salt. Int. J. Mol. Sci. 24(5), 4294 (2023).
doi: 10.3390/ijms24054294
pubmed: 36901725
Mule, G. et al. Influence of metabolic syndrome on hypertension-related target organ damage. J. Intern. Med. 257(6), 503–513 (2005).
doi: 10.1111/j.1365-2796.2005.01493.x
pubmed: 15910554
Gilstrap, L. G. & Wang, T. J. Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin. Chem. 58(1), 72–82 (2012).
doi: 10.1373/clinchem.2011.165712
pubmed: 22125305
Upadhyay, R. K. Emerging risk biomarkers in cardiovascular diseases and disorders. J. Lipids. 2015(1), 971453 (2015).
pubmed: 25949827
Newell, S. A., Girgis, A., Sanson-Fisher, R. W. & Savolainen, N. J. The accuracy of self-reported health behaviors and risk factors relating to cancer and cardiovascular disease in the general population: a critical review. Am. J. Prev. Med. 17(3), 211–229 (1999).
doi: 10.1016/S0749-3797(99)00069-0
pubmed: 10987638